The Brainse ™ Adaptive Brainse ™ adaptive stimulation has obtained CE marking. This step represents a revolutionary advance in personalized care for patients with Parkinson’s disease thanks to innovative human-machine interface technology, considers the manufacturer Medtronic [1].
Deep brain stimulation
Parkinson’s disease is associated with invalidating motor symptoms (tremors, rigidity, akinesis) as well as speech, sleep and cognitive functions that deeply impact the quality of life of patients and their loved ones. It is estimated that 10 million people suffer from Parkinson’s disease worldwide. In France, more than 270,000 people are affected by the disease, or around 25,000 new cases per year. Currently, this neurodegenerative disease cannot be healed and the treatments offered aim to reduce the symptoms of the disease.
In addition to drug treatments, patients with Parkinson’s disease have benefited from deep brain stimulation (SCP) for 30 years, technology that transmits electrical signals to the brain to alleviate the symptoms of the disease. In this context, Medtronic has developed Brainsense ™ technology which allows you to record the electrical activity of neurons in real time. In addition, the Brainsense ™ stud identification functionality improves deep cerebral stimulation programming (SCP) by offering a faster and personalized approach to adapt the treatment to each patient. Thus, thanks to the Brainsense ™ functionality, some patients with Parkinson’s disease can now benefit from real -time adaptive therapy which automatically adjusts the intensity of stimulation according to their brain activity.
In France, the first uses of adaptive stimulation in Parkinsonian patients were carried out at the CHU de Bordeaux by the Pr Dominique Guehl and the Dr Edouard Courtin (clinical neurophysiology service of children and adults) and public assistance – Marseille hospitals, by the Pr Alexandre Eusebio (Neurology and pathology service of the Timone Hospital movement).
This approval is based on the results of the global study ADAPT-PDwhose first results were published in the newspaper NPJ Parkinson’s Disease .
Follow Medscape in French on Bluesky , Facebook , Instagram , Linkedin , Youtube.
Register for newsletters DE MEDSCAPE: Select your choices